Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 1a Trial of Oral AMT-126; Expands Clinical Pipeline

Go back to Applied Molecular Transport (AMTI) Reports First Patient Dosed in Phase 1a Trial of Oral AMT-126; Expands Clinical Pipeline
Armitec, Inc. (NASDAQ: AMTI) Delayed: 41.09 -0.98 (2.33%)
Previous Close $42.07    52 Week High $0.00 
Open $42.00    52 Week Low $0.00 
Day High $44.33    P/E N/A 
Day Low $40.16    EPS $0.00 
Volume 172,273